Multiple Dose Safety Study of PF-04802540 in Healthy Volunteers
A Phase I Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-04802540 After Multiple Oral Dose Administration To Healthy Adult Volunteers
  • Phase

    Phase 1
  • Study Type

  • Status

    Completed No Results Posted
  • Intervention/Treatment

    pf-04802540 ...
  • Study Participants

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple ascending doses of PF-04802540 administered orally to healthy adult subjects.
Evaluation of safety and pharmacokinetics
Study Started
Sep 30
Primary Completion
Jan 31
Study Completion
Jan 31
Last Update
Mar 19

Drug PF-04802540

Multiple ascending doses for 10 days; planned doses include 5, 10 and 15 mg capsules q12 hours, doses may be adjusted based on accumulating data

Drug Placebo

Placebo capsules q12 hours for 10 days

PF-04802540 Experimental

Placebo Placebo Comparator


Inclusion Criteria:

Males or females of non-childbearing capacity aged 21 to 55 years inclusive at screening.
Body mass index in the range of 18 to 30 kg/m2 and body weight>45 kg.
Healthy as determined by the investigator on the basis of screening evaluation.

Exclusion Criteria:

Use of prescription or nonprescription drugs
Any condition possibly affecting drug absorption
No Results Posted